(BPT) - There is a new study evaluating a promising potential new treatment for epilepsy called Rise. Clinics across the nation are currently seeking to enroll participants in this study between the ages of 18-75 who have been diagnosed with focal (partial) onset epilepsy and have experienced resistance to existing treatments.

Epilepsy is a chronic brain disorder that affects over 50 million people worldwide.¹ It is characterized by recurrent, unprovoked seizures, which can vary in intensity and frequency.¹ Despite numerous treatment options, about 40% of people with epilepsy do not achieve seizure control with current medications.² During National Epilepsy Awareness Month this November, we are highlighting the urgent need for new effective treatments.

Challenges of Living with Epilepsy

Living with epilepsy can be incredibly challenging. The unpredictable nature of seizures can make daily activities, such as driving, working, or even socializing, difficult and stressful.³ For many, the fear of a sudden seizure looms, impacting their quality of life. In addition to physical challenges, epilepsy can also bring about emotional and psychological burdens, such as anxiety, depression, and social isolation.¹

Hope on the Horizon

'Hearing about new clinical trials makes me feel hopeful. The epilepsy community needs a treatment option that helps control seizures with a favorable safety profile,' said Ilene Asuncion, who has been managing epilepsy for years. 'A new treatment option would feel like a light at the end of a long tunnel, and I'm optimistic that this research could make a real difference in our lives.'

Enrollment Information

The clinical trial is currently enrolling patients at sites across the United States. If you or someone you know is struggling with epilepsy and is interested in participating in the trial, please visit epilepsyresearchstudy.com for more information. Eligibility criteria for participating in the trial include individuals who:

• Are between the ages of 18 to 75
• Have been diagnosed with focal (partial) onset epilepsy for at least one year
• Have been unsuccessful with at least two anti-seizure medications (ASMs) and are currently on a stable dose of one to three ASMs
• Have at least four or more observable focal seizures every 28 days

The Rise clinical trial represents a significant step forward in the search for more effective epilepsy treatments. By participating, patients not only have the potential to possibly benefit from a new investigational therapy but also contribute to crucial research that could improve the lives of countless others in the future.

References:

1. World Health Organization. Epilepsy. Available at https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed August 6, 2024.
2. Ioannou P, Foster DL, Sander JW, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12(9):e2589. doi:10.1002/brb3.2589.
3. Epilepsy Foundation. Social Concerns. Available https://www.epilepsy.com/complications-risks/social-concerns#:~:text=Having%20seizures%20may%20make%20it,problems%20for%20so%20many%20people!. Accessed August 6, 2024.